Objectives: The objectives of the study were to examine whether prophylactic therapy in patients with migraine with aura affects the incidence of aura in migraine attacks, and to investigate whether there is a connection between the effect of prophylactic therapy on migraine aura and the quality of life of patients with migraine with aura. Study design: Cross-sectional study. Participants and methods: The study included 20 subjects who suffer from migraine with aura, and who are treated with prophylactic therapy (10 on monoclonal antibodies to CGRP/CGRP receptor, 10 on oral prophylactics rimegepant and lamotrigine). The research was conducted at the Headache Clinic of the University Hospital Centre Osijek's Neurology Department. An anonymous survey questionnaire structured for this research, along with the SF-36 and HIT-6 questionnaires were used as research instruments. Results: After the introduction of prophylactic therapy, a total of 70% of respondents reported a reduction in the frequency of aura occurrences by more than 50%, while 20% reported a reduction of less than 50%. The decrease in aura frequency was more pronounced in patients on oral prophylactics (particularly on rimegepant) compared to those on monoclonal antibodies. Respondents also reported an improved quality of life after the introduction of prophylactic therapy. Aura severly affected the quality of life of 15% of respondents, had a substantial impact on 10%, and affected the remaining respondents moderately or to a lesser extent. Conclusion: After the introduction of prophylactic therapy of migraine, the number of migraine days and the frequency of aura were reduced by more than 50% in most patients. More than half of the respondents stated that the aura, after introduction of the therapy, had little or no impact on their life, and more than half of the respondents reported that their health is better now than a year ago.